A cancer vaccine developed by Moderna and Merck reduced the recurrence of melanoma.Credit: Adam Glanzman/Bloomberg/Getty A personalized mRNA vaccine for melanoma reduced the risk of the cancer returning in a phase III clinical trial, the companies behind the trial announced this week. The vaccine — which relies on the same mRNA technology used to develop
